• 407-549-3929
  • info@gapsos.com


Immunotherapy and Meningioma
Timothy Allen*, Ariel Sheikkhon, Shoja E Razavi, Naveed Basha Court
Global Allied Pharmaceuticals, Center for Excellence in Research and Development, USA.
*Corresponding Author: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and
Development, 160 Vista Oak Dr. Longwood, FL 32779, USA.

The most typical form of intracranial tumour is meningioma. Both the brain and spinal cord are covered by a very fine membrane. Meningioma originates from the arachnoids cap cells, which are present in this membrane.

[1] According to the report of the Central Brain Tumor Registry of the United States, in 2010, more than 170,000 cases were reported to be diagnosed in the years 2004-2006. Additionally, in the same year, approximately 155 death cases were recorded out of a population of 7,767 in the age group of 0-14 and 24 death cases out of a population of 3,009 in the age group of 15-19.[2] In the US, reported rates were marginally higher for black non-Hispanics (7.11 per 100,000 person-years) than for white non-Hispanics and Hispanics (6.14 and 6.30 per 100,000 years), respectively.[2] Western countries like North America and Europe were found to have higher incidence compared to African and Asian countries.[3.4]

It represents more than 33.8% of all the primary tumors related to thecentral nervous system.[3] The incidence rates range from 0.3 per 100,000 in children[4] to 40 per 100,000 in individuals above 85 years of age.[5]According to the National Cancer Database, the survival rate for meningioma was found to be 69% over a period of five years.[6] There is an annual increase of about 7.8 cases per 100,000, out of which only 25% are found to be symptomatic.[7] It includes different histopathologic and genetic characteristics. Females show predominance with a male-to female ratio of 1:1.4 to 2.6[8] and the incidence of 41.67% was observed at the age of 85 or above, which was the highest rate among all the age groups.